TABLE 1.
Whole cohort, n = 113 | |
---|---|
Females a | 91 (80.5) |
Age, b years | 34.2 (8.6) |
MS disease duration, b years | 7.0 (6.4) |
OCB positivity a | 110 (97.3) |
Relapse in year before baseline a | 112 (99.1) |
No. of relapses in year before baseline c | 1 (0–3) |
EDSS at baseline c | 1.0 (0–6.5) |
EDSS progression in year before baseline a | 11 (9.7) |
SDMT b | 55.3 (9.8) |
Received DMT before baseline a | 81 (71.7) |
No. of DMTs received before baseline c | 1 (0–4) |
Newly initiated DMT | |
Interferon β a | 32 (28.3) |
Glatiramer acetate a | 32 (28.3) |
Fingolimod a | 24 (21.2) |
Natalizumab a | 25 (22.1) |
Previous optic neuritis a | 22 (19.5) |
pRNFL thickness,μm, at baseline b | 92.4 (12.2) |
GCIPL thickness, μm, at baseline b | 81.1 (12.0) |
Abbreviations: DMT, disease‐modifying treatment; EDSS, Expanded Disability Status Scale; GCIPL, macular ganglion cell and inner plexiform layer; MS, multiple sclerosis; OCB, oligoclonal bands; pRNFL, peripapillary retinal nerve fiber layer; SDMT, Symbol Digit Modalities Test.
Number (percentage).
Mean and standard deviation.
Median and range.